Case Study: a Japanese midsize global pharma and biotech company achieves 100% on-time submissions and 50% cost savings with Freyr

a Japanese midsize global pharma and biotech company achieves 100% on-time submissions with FREYR

The Japanese midsize global pharma and biotech company faced challenges with high attrition rates and unstable resources, alongside navigating misaligned processes and unclear regulations for its Canadian New Drug Submissions (NDS) and SPMs. They engaged FREYR for comprehensive submission publishing support and strategic regulatory partnership.

FREYR implemented a scalable hybrid staffing model, combining onshore and offshore resources to provide 24/7 support. This solution, which included process consulting to define and maintain best practices, resulted in 100% on-time submissions with zero HA rejections. FREYR achieved over 50% cost savings for the customer while enhancing overall process efficiency.